BioTissue Reported Phase 2 Dry Eye Therapy Results
The Miami-based company shared data from a clinical study on its TTAX03 treatment for dry eye patients.
Updated on Oct. 10, 2026 in Biotech
Live Poll
Do you trust medical treatments developed from human birth tissue to be safe and effective?
BioTissue announced Phase 2 clinical study results for its dry eye therapy candidate, TTAX03. The findings showed positive safety data and symptom improvement in participants who received the treatment.
Why it matters
The study provides key safety data on TTAX03, marking a milestone in the development of a potential new treatment for dry eye. Further research is now required to define optimal dosing and treatment regimens for the therapy.
The study randomized 74 patients to receive either saline or one of three TTAX03 concentrations applied via a bandage contact lens for five days. Safety was monitored over a 12-week period with visual acuity measured at Day 85.
The players
BioTissue
This Miami-based biotechnology company focuses on developing ocular therapies and has performed over 1 million human implants since its inception.
American Academy of Ophthalmology
This professional medical organization hosts an annual meeting that serves as a primary venue for ophthalmologists to review the latest clinical research.
The details
The prospective, double-masked study showed no treatment-related serious adverse events among participants. Patients in the highest dose group exhibited the greatest improvement in symptoms and higher rates of corneal staining resolution.
Timeline
BioTissue announced the Phase 2 study results on October 9, 2026.
The American Academy of Ophthalmology meeting takes place October 9-12, 2026.
Best-corrected visual acuity was measured at the Day 85 timepoint.
The Tech Race
BioTissue is leveraging the American Academy of Ophthalmology Annual Meeting to showcase data that bolsters its position in the competitive dry eye market. This move aligns with a broader industry push to validate novel therapeutics through rigorous peer-reviewed clinical testing.
Patients currently suffering from dry eye should note that this remains an investigational study, meaning the treatment is not yet available for public use. Future advancements depend on further clinical research to confirm efficacy and determine long-term therapeutic benefits.
The takeaway
This Phase 2 study represents a critical step for BioTissue in validating TTAX03 as a viable treatment option for ocular conditions. While the initial safety and symptom data are promising, clinical development timelines require patience before such therapies reach the commercial market.
Further reading
For additional context on local industry developments, visit Biotech.
More information
View the American Academy of Ophthalmology conference program for more details on the scientific sessions.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust medical treatments developed from human birth tissue to be safe and effective?
